Mayo Clinic's Center for Individualized Medicine has achieved a significant milestone with its Tapestry study, generating the clinic's largest-ever collection of exome data, which include genes that code for proteins — key to understanding health and disease.
Hackensack Meridian Pascack Valley Medical Center is proud to announce the launch of its new Breast Health Program, a comprehensive service designed to provide top-tier breast health care in a compassionate, patient-centered environment. The program is dedicated to early detection, accurate diagnosis, and effective treatment of breast cancer, which affects 1 in 8 women in the U.S. during their lifetime.
Roswell Park President and CEO Candace S. Johnson, PhD, today introduced the cancer center’s first Physician in Chief — and the slate of experts appointed to tackle the most pressing opportunities and challenges related to cancer treatment, outcomes and delivery of care.
Through a partnership with a nearby university, the middle schoolers collected and analyzed environmental samples to find new antibiotic candidates. One unique sample, goose poop collected at a local park, had a bacterium that showed antibiotic activity and contained a novel compound that slowed the growth of human melanoma and ovarian cancer cells in lab tests.
As part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children’s Hospital of Philadelphia, the University of Pittsburgh and Weill Cornell Medicine discovered a novel cause of cytokine storm — the extreme inflammatory response associated with increased risk of death in COVID-19 infection.
20221027104337.jpg&width=300&height=300)
Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.
Physician-scientists from Rutgers Cancer Institute and RWJBarnabas Health will showcase a diverse range of hematology/oncology data from their clinical research program at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and online) from December 7-10, 2024.
New this year, the holiday display in Sunflower Bank’s Downtown lobby, 201 E. Main, Suite 200, includes lavender ribbons to support our community’s cancer warriors. These ribbons represent awareness and solidarity for all who have shown strength in their fight against any form of cancer.
UM researchers recently developed a new genomics method with the potential to reveal the genetic mechanisms behind human health and disease. The recent publication in the journal Genome Biology offers an innovative new pathway to study the root causes of diseases like cancer and dementia to someday allow for early detection.
Research pathologist wins national award for AI-powered immuno-oncology tool that predicts lung cancer treatment outcomes
Chelsey Schlechter, PhD, MPH, has been chosen as a Cancer Moonshot Scholar. She is one of eleven researchers from across the country who have been selected for the prestigious honor.
Yale Cancer Center (YCC) researchers at Yale School of Medicine will present new research at the 66th annual American Society of Hematology (ASH) annual meeting in San Diego, Calif., December 7-10. Known as “the premier event in classical and malignant hematology”, the ASH meeting includes oral and poster presentations, as well as workshops and educational sessions for hematology professionals and advocates.
RWJBarnabas Health, together with Rutgers Cancer Institute, has been named to Becker’s Hospital Review’s 100+ Hospitals and Health Systems with Great Oncology Programs list for 2024, for the second consecutive year.
BACKGROUNDRecent advancements in nanomedicine have highlighted the potential of exosome (Ex)-based therapies, utilizing naturally derived nanoparticles, as a novel approach to targeted cancer treatment. AIMTo explore the targetability and
Endometrial/uterine and ovarian cancers have few effective treatment options outside of surgery. Now, researchers have identified a set of DNA repair proteins that may become a target for the treatment of these cancers
Showing results
1–1 of 1
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
